Immunoglobulin A (IgA)
Product Sizes
1 mg
16-16-090701-1MG
5 mg
16-16-090701-5MG
10 mg
16-16-090701-10MG
About this Product
- SKU:
- 16-16-090701
- Additional Names:
- IgA|In Vitro Diagnostic, Glycoproteomics, ELISA, Cancer, Chromatography Binding, Anaphalaxis, Infection, Autoimmune Diseases, Kidney Injury, Rheumatoid Arthritis
- Application:
- ELISA
- Buffer:
- Frozen in 100 mM Tris-HCl, pH 8.0, with 100 mM NaCl and 0.05% NaN3.
- CE/IVD:
- RUO
- Extra Details:
- Serum immunoglobulin A (IgA) constitutes the second most abundant antibody class in human plasma (0.4-2.2 mg/mL), existing predominantly as monomeric IgA1 (80%) with lesser IgA2 contributions. Unlike secretory IgA-a dimeric mucosal protector featuring J-chains and a secretory component-serum IgA engages FcA AlphaRI (CD89) on myeloid cells to orchestrate systemic immunity. Monomeric serum IgA suppresses inflammation via inhibitory ITAMi signaling, while immune complexes activate phagocytosis, cytokine release, and antibody-dependent cellular cytotoxicity, balancing pathogen clearance and tissue homeostasis. Dysregulation of serum IgA underpins multiple pathologies. Selective IgA deficiency (sIgAD), the most common primary immunodeficiency, elevates risks for recurrent infections and autoimmune disorders like systemic lupus erythematosus (SLE) and celiac disease. Conversely, elevated serum IgA associates with IgA nephropathy, where galactose-deficient IgA1 deposits in renal glomeruli trigger complement-mediated inflammation and progressive kidney failure. Hyper-IgA levels may also signal immunodeficiency syndromes or multiple myeloma, particularly when beta-migrating monoclonal proteins complicate electrophoresis interpretation. The IgA2 subclass, distinguished by reduced sialylation, exhibits heightened pro-inflammatory activity linked to rheumatoid arthritis severity. Clinically, serum IgA quantification aids immunodeficiency diagnosis and myeloma monitoring, where nephelometric assays outperform traditional electrophoresis. Therapeutic strategies targeting FcA AlphaRI or aberrant IgA production, such as monoclonal antibodies against B-cell activating factor (BAFF), show promise in autoimmune and renal diseases. Additionally, engineered IgA antibodies are being explored for enhanced neutrophil-mediated tumor cytotoxicity, highlighting its expanding translational potential.
- Formulation:
- Frozen in 100 mM Tris-HCl, pH 8.0, with 100 mM NaCl and 0.05% NaN3.
- Molecular Weight:
- 160,000 Da
- Physical State:
- Frozen
- Purity:
- ≥95%
- Purification:
- Liquid Chromatography Methods
- Shipping Conditions:
- Dry Ice
- Source:
- Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
- Storage Conditions:
- Please refer to datasheet
- Supplier:
- Athens Research & Technology Inc.
- Type:
- Antibody: Isotype Controls
